A method of treating diabetes can include administering a therapeutically effective amount of a composition comprising a soluble protein fraction obtained from epidermal gel secretions of catfish to a patient in need thereof. The soluble protein fraction can include soluble proteins and lipids from the epidermal gel secretions of catfish. The soluble protein fraction can include about 87% of the soluble proteins and about 13% of the lipids. The composition can be administered by intraperitoneal (IP) or sub-cutaneous (SC) injection.

A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an -polylysine (EPL) including -poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.

A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an -polylysine (EPL) including -poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.

Compositions, methods of use, and pharmaceutical preparations useful for modulation of immune responses are disclosed herein. In one embodiment a composition is extracted from immune organs or leukocytes derived from members of the chondrichthyes family through dialysis. Said immune modulator is useful for treatment of conditions requiring stimulations or regulation of immunity. In one embodiment, said immunomodulator controls T cell activation by modulation of cytokine production.

The present invention relates to cosmetic compositions obtained or obtainable from Salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for reducing or preventing the cosmetic appearance or prevalence of wrinkles, fine lines, hyperpigmentation, laxity, dry skin, scaling and/or transepidermal water loss in skin of a mammalian animal.

The present invention is directed to a pharmaceutical composition comprising an Nrf2-inhibitor. Likewise, the present invention is directed to a pharmaceutical composition for use in the treatment of ASD in a patient, comprising: determining whether the patient suffers from ASD subtype 1 and administering a therapeutically effective amount of an Nrf2-inhibitor if the patients suffers from ASD subtype 1, wherein determining whether the patient suffers from ASD subtype 1 comprises administering the patient an Nrf2-activator and identifying the patient as suffering from ASD subtype 1 if he shows a negative response.

The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.

The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises,: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD. Likewise, the present invention is directed to an Nrf2-activator for use in differentiating between autism spectrum disorder (ASD) phenotype 1 patients, phenotype 2 patients and other ASD patients, wherein the Nrf2-activator is administered to a subject, wherein a phenotype 1 patient is identified by a negative response, a phenotype 2 patient is identified by a positive response and other ASD patients are identified by the absence of a positive and a negative wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.

The invention relates to a strengthened T-cell modulator with a strength of 10.sup.12 leukocytes/mm.sup.3, produced from a dialysed extract of leukocytes from the spleen of selachimorpha or sharks, which contains a maximum of 10,000 Da., in the form of a powder. The invention also relates to the use thereof for producing a medicament for treating the disease known as vitiligo.